ライフサイエンスコーパス: dopamine antagonist

1 was antagonized by SCH 23390, a D1 selective dopamine antagonist.

2 ation, and were abolished in the presence of dopamine antagonists.

3 s were applied to 29 chemically diverse D(1) dopamine antagonists.

4 voked in the presence of a broad spectrum of dopamine antagonists.

5 Binding of the dopamine antagonist [125I]iodosulpride to D3 receptors w

6 s were found elevated again at the time when dopamine antagonists and agonists were effective: betwee

7 in this study suggest that first-generation dopamine antagonists and clozapine should be avoided whe

8 to D1 and D2 receptors for most nonselective dopamine antagonists and had affinities for most of the

9 In a network meta-analysis, oral dopamine antagonists and tachykinin-1 antagonists were m

10 t that muscarinic agonists act as functional dopamine antagonists and that they could become a novel

11 s neurokinin-1 antagonists, corticosteroids, dopamine antagonists, and cholinergic antagonists, have

12 at are generally resistant to treatment with dopamine antagonist antipsychotic drugs.

13 Conversely, the dopamine antagonist aripiprazole exacerbates sepsis mort

14 examining whether intra-basalis perfusion of dopamine antagonists attenuates this increase.

15 819 women exposed and 55 289 not exposed to dopamine antagonists between January 1, 1989, and June 3

16 Here, an infusion of the dopamine antagonist cis-(z)-Flupenthixol into the amygda

17 Microinjections of the dopamine antagonist cis-flupentixol or the cholinergic a

18 However, raclopride, a D2 selective dopamine antagonist, completely blocked 7-OH-DPAT-induce

19 mediate and delayed effects of the intra-PFC dopamine antagonist demonstrate a facilitation of VTA BS

20 omen who used prolactin-elevating antiemetic dopamine antagonists despite having different breast can

21 Microinjections of the irreversible dopamine antagonist EEDQ (N-ethoxycarbonyl-2-ethoxy-1,2-

22 The dopamine antagonists, eticlopride (D2/3, 0.25 mg/kg day)

23 blocked by intra-mPFC administration of the dopamine antagonist flupenthixol.

24 re blocked by previous injection of either a dopamine antagonist (flupentixol) or an opioid antagonis

25 re abolished with topical application of the dopamine antagonist fluphenazine.

26 U-99194A, a D3 selective dopamine antagonist, had no significant effect on 7-OH-D

27 Systemic injections of the dopamine antagonist haloperidol (0.1-2.5 mg/kg) induced

28 Subsequent injection with the dopamine antagonist haloperidol (1.0 mg/kg, s.c.) revers

29 The dopamine antagonist haloperidol blocked the PSP enhancem

30 administration of a nonakinesia dose of the dopamine antagonist haloperidol.

31 This effect was prevented by the dopamine antagonist haloperidol.

32 between antipsychotics, but first-generation dopamine antagonists haloperidol (standardized mean diff

33 eptor antagonist, D-CPPene, the non-specific dopamine antagonist, haloperidol, and the purinergic ago

34 crease in calmodulin would be blocked by the dopamine antagonist, haloperidol, or the NMDA antagonist

35 le rats, NAcC perturbation with glutamate or dopamine antagonists impeded responses to the incentive

36 The role of dopamine and dopamine antagonists in the processing of such informati

37 Finally, a dopamine antagonist injected into the nucleus accumbens

38 midbrain dopaminergic neurons and blocked by dopamine antagonists injected into the nucleus accumbens

39 e not been explored beyond one study showing dopamine antagonist-like effects of intra-Acb amylin on

40 ard emotionally salient information and that dopamine antagonists may act by attenuating this bias.

41 The authors investigated the effect of a dopamine antagonist on perception of, and memory for, em

42 ach was implemented to explore the effect of dopamine antagonists on firing patterns without altering

43 ctivity (NTLI); (2) the effects of selective dopamine antagonists on ibogaine-induced changes in NT c

44 stigated the effects of haloperidol, a D2/D3 dopamine antagonist, on social attributions.

45 cillation is interrupted by application of a dopamine antagonist onto the cortical surface the dyskin

46 hermore, the patient had no prior history of dopamine antagonist or estrogen medication use.

47 Specifically, this research shows that a dopamine antagonist, pimozide, changes response rates th

48 The administration of the dopamine antagonists, pimozide and alpha-flupenthixol, t

49 Administration of the dopamine antagonists raclopride (0.1 and 0.5 mg/kg), SCH

50 In contrast, vertebrate D2-like and D1-like dopamine antagonists result in akinesic states, and D1-l

51 monoamine uptake inhibitor bupropion and the dopamine antagonist risperidone.

52 rticipant a dopamine precursor (levodopa), a dopamine antagonist (risperidone), and a placebo (lactos

53 lasses were efficacious: in rank order, oral dopamine antagonists (RR, 0.58; 95% CI, 0.44-0.77; P-sco

54 Pretreatment with the D1 dopamine antagonist SCH 23390 [R-(+)-7-chloro-8-hydroxy-

55 so when the rats were pretreated with the D1 dopamine antagonist SCH 23390.

56 These effects were blocked by the D2-like dopamine antagonist sulpiride (1 microM).

57 modulations of dopaminergic tone, i.e., the dopamine antagonist sulpiride and the dopamine precursor

58 The dopamine antagonists sulpiride and spiperone were both i

59 were protected from reaction by a reversible dopamine antagonist, sulpiride.

60 were protected from reaction by a reversible dopamine antagonist, sulpiride.

61 were protected from reaction by a reversible dopamine antagonist, sulpiride.

62 For example, haloperidol is a potent dopamine antagonist that is used to treat psychotic diso

63 between rod/cone pairs in the presence of a dopamine antagonist to activate Cx36, suggesting that th

64 ncreased the likelihood of scouting, whereas dopamine antagonist treatment decreased it.

65 Thus, it seems that the same dopamine antagonist treatments that have been shown to d

66 Antipsychotic dopamine antagonist use may confer a small but significa

67 Dopamine antagonist use was not associated with risk of

68 sed the possibility that prolactin-elevating dopamine antagonists used to treat psychotic disorders m

69 The increased risk of breast cancer among dopamine antagonist users was not explained by increased

70 east cancer risk profiles than antipsychotic dopamine antagonist users.

71 Use of antipsychotic dopamine antagonists was associated with a 16% increase